AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab

AstraZeneca ($~AZN) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca is running a Phase 3b trial called TAPER (official title: “A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab”). The study aims to see whether patients with severe asthma who are already controlled on Tezepelumab can safely reduce their background daily asthma medicines while keeping symptoms stable. This matters because stepping down treatment without losing control could lower overall drug burden and costs, and further support Tezepelumab’s value in long-term asthma care.

Intervention/Treatment: The only treatment in the study is Tezepelumab, a prescription asthma drug (a biologic) designed for patients with severe asthma. Participants already use medium to high doses of inhaled steroids plus a long-acting bronchodilator, with possibly one other controller. The purpose is to see if Tezepelumab is strong enough to allow doctors to cut back on these background inhalers while still keeping flare-ups and symptoms in check.

Study Design: This is an interventional, Phase 3b study with one group only. Everyone in the trial receives Tezepelumab; there is no random assignment to different treatments and no placebo arm. The trial is open-label, meaning both doctors and patients know they are on Tezepelumab. The main goal is treatment-focused: to test whether stepping down maintenance therapy is safe and effective for people with severe asthma who remain on Tezepelumab.

Study Timeline: The study was first submitted in late November 2025, marking the formal start of regulatory tracking and trial set-up. The trial is currently listed as “recruiting,” showing that patient enrollment is still underway. The latest update to the record was posted on February 4, 2026, which signals that the sponsor is actively maintaining the listing and that the protocol and timelines are current. Primary completion and full completion dates have not yet been reported, reflecting that the study is still in progress.

Market Implications: For investors in AstraZeneca (AZN), this update adds another potential leg to the Tezepelumab story. If the study shows patients can safely cut back on background inhalers while staying on Tezepelumab, it could strengthen the drug’s positioning as a premium, simplifying therapy in severe asthma. That can support sustained pricing power and wider adoption among specialists. Positive data would likely be viewed as a long-term tailwind for AZN’s respiratory portfolio, especially as payers increasingly look for evidence that high-cost biologics reduce overall treatment burden and healthcare use. Competitors in severe asthma biologics, including players focused on IL-5 and IL-4/13 pathways, may face added pressure if Tezepelumab can demonstrate both strong control and treatment simplification. While no immediate impact on earnings is expected from this update alone, ongoing progress in this trial should be monitored as a potential driver for sentiment around AZN’s respiratory growth outlook.

The TAPER study remains ongoing and updated, with further details available on the ClinicalTrials portal under NCT07363642.

To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.